CHF 0.0015 (-25%): IGEA Pharma IGPH.SW (SIX) pre-market 25 Feb, heavy volume
We see IGEA Pharma N.V. (IGPH.SW) trade at CHF 0.0015 in the pre-market session on 25 Feb 2026, down 25.0% on the day with 2,033,000 shares changing hands. The spike in volume makes IGPH.SW stock one of the most active names on SIX this morning and raises liquidity and short-term risk questions. We outline the drivers: raw price action, market-cap structure, recent financials and a concise Meyka AI forecast to help frame potential next steps for traders and investors.
IGPH.SW stock: price, volume and market snapshot
IGEA Pharma (IGPH.SW) opened pre-market at CHF 0.0015 after a prior close of CHF 0.0020, with a day high of CHF 0.0020 and day low of CHF 0.0015. Market capitalisation stands near CHF 505,545 with 337,030,016 shares outstanding. Average volume is 193,941; today’s volume of 2,033,000 equals a relative volume of 10.48, confirming why IGPH.SW stock ranks among most active names on SIX.
Financials and valuation measures for IGPH.SW stock
Recent reported metrics show negative earnings with EPS -0.03 and an implied P/E of -0.05, reflecting ongoing losses. Key ratios are strained: current ratio 0.19, cash per share CHF 0.000089, and book value per share -0.00713. These figures point to weak liquidity and negative equity on the balance sheet, which explains both the low price and elevated volatility in IGPH.SW stock.
Sector context: healthcare trends that affect IGPH.SW stock
IGEA operates in Healthcare — Medical Diagnostics & Research — where larger peers show stronger margins and higher P/Es. The Swiss/European healthcare sector is positive year to date while small-cap med-tech names face funding and commercialization headwinds. For IGPH.SW stock that sector strength offers opportunity but also highlights a gap in scale, where product traction must outpace cash burn to change valuation trends.
Meyka AI stock grade and analyst context for IGPH.SW stock
Meyka AI rates IGPH.SW with a score out of 100: 62.58 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects a middling outlook driven by high volatility, thin liquidity and negative earnings. These grades are informational only and not investment advice.
Technical and trading signals: what the volume surge means for IGPH.SW stock
Price averages show weakness: 50-day average CHF 0.00214 and 200-day average CHF 0.00517, both above today’s price. The volume surge and relative-volume 10.48 suggest short-term sellers or a block trade execution. For traders, tight bid-ask spreads may not exist and stop-loss slippage is likely, so position sizing and execution strategy matter when trading IGPH.SW stock.
Risks and opportunities tied to IGPH.SW stock
Upside depends on commercialization of Alz1 and other med-tech products and on improved cash flow. Downside drivers include continued cash burn, negative shareholders’ equity and low current ratio, which could force dilution. Given the small market cap and high relative volume, IGPH.SW stock remains high risk but could offer episodic rebounds if clinical or sales milestones are announced.
Final Thoughts
Key takeaways for IGPH.SW stock: the pre-market move to CHF 0.0015 on 25 Feb 2026 with 2,033,000 shares traded makes the name one of the most active on SIX today. Financials show negative EPS and weak liquidity, so volatility and dilution risk remain high. Meyka AI’s forecast model projects CHF 0.0030, implying an upside of approximately +100.00% versus the current CHF 0.0015. Forecasts are model-based projections and not guarantees. For active traders we recommend a cautious, short-horizon approach; for investors we flag the need for clear operational milestones before increasing exposure. See the company site for filings and product updates and our Meyka stock page for realtime alerts and AI-powered market analysis.
FAQs
What is the current price and trading status of IGPH.SW stock?
IGPH.SW stock trades pre-market at CHF 0.0015 on 25 Feb 2026, down 25.0%, with volume at 2,033,000. The large volume makes liquidity and execution risk higher than usual.
What grade does Meyka AI assign to IGPH.SW stock and why?
Meyka AI rates IGPH.SW with a score out of 100: 62.58 | Grade B | Suggestion: HOLD. The grade factors sector comparison, financial growth, key metrics and analyst signals, and it is informational not investment advice.
What is Meyka AI’s near-term forecast for IGPH.SW stock?
Meyka AI’s forecast model projects CHF 0.0030, implying about +100.00% from the current CHF 0.0015. Forecasts are model-based projections and not guarantees.
What are the main risks for investors in IGPH.SW stock?
Main risks include negative EPS, low current ratio (0.19), negative book value per share, and potential dilution from capital raises. These make IGPH.SW stock a high-risk holding for longer-term investors.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.